AprilK.S.SalamaMD

Oncology • Durham, NC

Hematologic Oncology, Melanoma

Assistant Professor, Medicine, Duke Univ Sch of Med

Join to view full profile

Dr. Salama is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Salama's full profile

Already have an account?

Office
Duke Medical Ctr
# Dumc
Durham, NC 27710
Phone+1 888-275-3853

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 2007 - 2010
University of ChicagoResidency, Internal Medicine, 2004 - 2007
University of North Carolina at Chapel Hill School of MedicineClass of 2004

Certifications & Licensure

NC State Medical License 2010 - 2025
IL State Medical License 2004 - 2011
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma Start of enrollment: 2012 Jun 03
Completed
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. Start of enrollment: 2013 Jul 01
Terminated
Phase 1, Phase 2
A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma Start of enrollment: 2014 Apr 01
Withdrawn
Phase 1
Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma Start of enrollment: 2014 May 01
Completed
Phase 1
Pan Tumor Rollover Study Start of enrollment: 2019 Aug 09
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Molecular and immune landscape of tumours in geriatric patients with non-small cell lung cancer, melanoma and renal cell carcinoma.
Khalil Choucair, Andrew Elliott, Matthew James Oberley, Phillip Walker, April K Salama
BMJ Oncology. 2025-01-01
Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma.
Jeffrey Weber, Waqas Haque, Svetomir N Markovic, April K S Salama, Inderjit Mehmi
The Oncologist. 2024-11-19
Multiple Options: How to Choose Therapy in Frontline Metastatic Melanoma.
Lucy Boyce Kennedy, April K S Salama
Current Oncology Reports. 2024-08-01

Lectures

Dabrafenib and trametinib in patients with tumors with BRAF V600E/K mutations: Results from the molecular analysis for therapy choice (MATCH) Arm H.
2019 ASCO Annual Meeting - 6/1/2019
Clinical Features of Immune Checkpoint Inhibitor-Associated Autoimmune Hemolytic Anemia: A Series of 14 Cases
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

April Salama’s War on Metastatic MelanomaJune 22nd, 2021
More Options for Treating MelanomaSeptember 28th, 2021
Skin Cancer Not 'Relatively New,' Dates Back More Than 200 Years | Fact CheckAugust 6th, 2023